NEW YORK (GenomeWeb News) – Epigenomics today reported flat third quarter revenues year over year as the firm awaits US Food and Drug Administration clearance for its flagship Epi proColon colorectal cancer screening test.

The Berlin-based molecular diagnostics firm reported revenues of €263,000 ($356,000) for the quarter ended Sept. 30, compared to €272,000 for the third quarter of 2012. In a report to investors, the firm said that a decrease in licensing revenue was offset by a more than 23 percent increase in product revenue year over year to €110,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.